0
Selected Reports |

Etanercept for Refractory Ocular Sarcoidosis*: Results of a Double-Blind Randomized Trial

Robert P. Baughman, MD, FCCP; Elyse E. Lower, MD; Deborah A. Bradley, MD; Lawrence A. Raymond, MD; Adam Kaufman, MD
Author and Funding Information

*From the Departments of Internal Medicine (Drs. Baughman, Lower, and Bradley) and Ophthalmology (Drs. Raymond and Kaufman), University of Cincinnati Medical Center, Cincinnati, OH.

Correspondence to: Robert P. Baughman MD, 1001 Holmes, Eden Ave, University of Cincinnati Medical Center, Cincinnati, OH 45267-0565; e-mail address bob.baughman@uc.edu



Chest. 2005;128(2):1062. doi:10.1378/chest.128.2.1062
Text Size: A A A
Published online

Purpose: Study a tumor necrosis factor receptor antagonist (etanercept) in the treatment of chronic ocular sarcoidosis.

Subjects and methods: Eighteen patients with ocular sarcoidosis and ongoing inflammation in the eyes. All patients had received at least 6 months of therapy with methotrexate and were currently receiving corticosteroids. Patients were randomized to receive either etanercept, 25 mg subcutaneously twice a week, or placebo in a double-blind randomized trial. Treatment for ocular inflammation with systemic and local corticosteroids at the beginning and end of 6 months of treatment was noted. All patients underwent an ocular examination at the beginning and the end of the study by one ophthalmologist who was unaware of what treatment the patient was receiving.

Results: Three of the patients treated with etanercept and one treated with placebo were being treated with lower doses of corticosteroids by the end of the study. However, three of the etanercept patients and one of the placebo patients required larger doses of corticosteroids by the end of the study. The ophthalmology global assessment improved for two of the etanercept-treated patients and three of the placebo-treated patients.

Conclusion: For most patients, therapy with etanercept was not associated with a significant improvement in their chronic ocular disease.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Childhood sarcoidosis: Louisiana experience. Clin Rheumatol 2016;35(7):1879-84.
Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol 2016;12(8):817-25.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543